Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 26, 2022

Trastuzumab-Deruxtecan in Patients With HER2-Positive Breast Cancer With Active Brain Metastases

Annals of Oncology


Additional Info

Annals of Oncology
165MO - Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
Ann. Oncol 2022 May 04;na(na)na, R Bartsch, AS Berghoff, J Furtner, et al

Further Reading